Browsing by Subject "GPCR"

Deciphering natural odor plumes with dynamic changes in odor concentrations presents a common challenge to all animals. A fundamental challenge in studying the organization principles of the olfactory system to encode odor concentration information is the lack of comprehensively identified sets of activated odorant receptors (ORs) across an odorant concentration range inside freely behaving animals. In mammals, this has recently become feasible with high-throughput sequencing-based methods that identify populations of odorant activated ORs in vivo. In this study, we characterized the mouse OR repertoires activated by two odorants, acetophenone (ACT) and 2,5-dihydro-2,4,5-trimethylthiazoline (TMT), from 0.01% to 100% (v/v) concentrations. We also investigated the OR repertoires for structural derivatives of TMT (component of fox odor) such as 2­methyl-2-thiazoline (2MT) and 2,4,5-Trimethylthiazole (nTMT) and 2-sec-butyl-4,5-dihydrothiazole (SBT) for 1% and 100% (v/v) concentrations. We used a combination of in vivo, in situ and in silico approaches to investigate ORs with distinct sensitivities to the tested odorants. We examined Olfr923, which we identified to be one of the most sensitive ACT ORs based on our pS6-IP-Seq data. Using a mouse line that genetically labels Olfr923 positive axons, we provide evidence that ACT activates the Olfr923 glomerulus in the olfactory bulb. This study sheds light on the active process in which unique OR repertoires may collectively facilitate the discrimination of odorant concentrations. Together, these odorant receptors may shape the dynamic aspects of olfactory sensitivity and facilitate odorant intensity coding.

G-protein coupled receptors (GPCRs) are pivotal to multiple physiological processes, including neuronal functions such as neurotransmission and memory formation. Consequently, aberrant GPCR signaling has been implicated in complex psychiatric disorders. Our ability to develop efficient therapeutic strategies depends on our understanding of the molecular factors that govern GPCR activity. We performed a genome-wide CRISPR interference screen using a fluorescent cAMP-dependent transcriptional reporter and identified 95 novel regulators that had no previous connection to the GPCR/cAMP pathway. We functionally validated eight regulators and showed that they control distinct steps of the pathway. One of these, RNA binding motif 12 (RBM12), is a novel potent negative regulator of the GPCR/cAMP pathway. Truncating RBM12 mutations are implicated in highly penetrant schizophrenia and defective brain development, yet its cellular function is unknown. To investigate its role in GPCR/cAMP signaling, we performed CRISPR-based gene editing in two complementary cellular models: experimentally tractable HEK293 cells and physiologically relevant human induced pluripotent stem cell-derived neurons. We found that RBM12 deficiency leads to hyperactive cAMP accumulation, PKA activity, and downstream CREB-dependent transcriptional responses in response to the activation of stimulatory GPCRs with key functions in neurobiology (beta-adrenergic, dopamine, and adenosine). We observed that the cAMP signaling and PKA activity are independently subject to regulation by RBM12. This signaling hyperactivity is conserved in the two cellular model systems. We further show that schizophrenia-associated truncating RBM12 mutations (c.2377G>T and c.2532delT) failed to rescue the signaling hyperactivation due to possible loss-of-function and protein stability defect. In agreement with its activity as an RNA-binding protein, we show that RBM12 depletion led to altered expression of genes with established roles in the signaling pathway, including an upregulation of cyclases and the protein kinase A catalytic subunits as well as a downregulation of phosphodiesterases. In addition, we observed aberrant gene expression in neurogenesis, neurodevelopment, and differentiation pathways. Together, these experiments provide critical insights into this uncharacterized gene and its function as a novel regulator of GPCR signaling. By uncovering the novel regulatory role of a schizophrenia-risk gene in GPCR signaling, we expand our understanding of the molecular basis of neuropsychiatric disorders and enable the identification of novel druggable targets.

Olfaction is one of the most primitive of our senses, and the olfactory receptors that mediate this very important chemical sense comprise the largest family of genes in the mammalian genome. It is therefore surprising that we understand so little of how olfactory receptors work. In particular we have a poor idea of what odorous chemicals are detected by most of the olfactory receptors in the genome, and for those receptors which we have paired with ligands, we know relatively little about how the structure of these ligands can either activate or inhibit the activation of these receptors. Furthermore the large repertoire of olfactory receptors, which belong to the G protein coupled receptor (GPCR) superfamily, can serve as a model to contribute to our broader understanding of GPCR- ligand binding, especially since GPCRs are important pharmaceutical targets.

In this dissertation, I explore the relationship between olfactory receptors and their ligands, both by manipulating the ligands presented to the olfactory receptors, as well as by altering the structure of the receptor itself by mutagenesis. Here we report the probable requirement of a hydrated germinal-diol form of octanal for activation of the rodent OR-I7 receptor by ligand manipulation, and the successful in vitro modeling and manipulation of ketamine binding to MOR136-1. We also report the results of a large-scale screen of 1190 human and mouse olfactory receptors for receptors activated by volatile general anesthetics, which has lead to the identification of 32 olfactory receptor-volatile general anesthetic pairs.

The neuromodulator dopamine signals through the dopamine D2 receptor (D2R) to modulate central nervous system functions through diverse signal transduction pathways. D2R is a prominent target for drug treatments in disorders where dopamine function is aberrant, such as schizophrenia. D2R signals through distinct G protein and β-arrestin pathways and drugs that are functionally selective for these pathways could have improved therapeutic potential. How D2R signals through the two pathways is still not well defined, and efforts to elucidate these pathways have been hampered by the lack of adequate tools for assessing the contribution of each pathway independently. To address this, Evolutionary Trace was used to produce D2R mutants with strongly biased interactions for either G protein or β-arrestin. Additionally, various permutations of these mutants were used to identify critical determinants of D2R functional selectivity. D2R interactions with the two major downstream signal transducers were effectively dissociated and G protein signaling accounts for D2R canonical MAP kinase signaling cascade activation. Nevertheless, when expressed in mice, the β-arrestin biased D2R caused a significant potentiation of amphetamine-induced locomotion, while the G protein biased D2R had minimal effects. The mutant receptors generated here provide a new molecular tool set that enable a better definition of the individual roles of G protein and β-arrestin signaling in D2R pharmacology, neurobiology and associated pathologies.

Extracellular chemical gradients provide signals that guide a broad spectrum of different cellular processes. By accurately sensing and responding to chemical gradients, immune cells can chase down invading pathogens, sperm cells can locate a distant egg, and growing axons can form connections in the developing nervous system. Haploid cells of the budding yeast Saccharomyces cerevisiae grow up gradients of pheromone in order to locate and fuse with nearby mating partners. Gradient sensing should be challenging for yeast, because they must detect a minute difference in concentration across their small cell bodies. Nevertheless, yeast cells can orient with remarkable accuracy in shallow pheromone gradients. Several mechanisms have been proposed to explain how yeast cells locate their partners, but it remains unclear whether, and to what degree each of the proposed mechanisms contributes.

We imaged fluorescent polarity probes in real time during mating events and found that cells located their partners in a multi-step process. First, cells placed a weak cluster of polarity proteins in approximately the correct location, despite a previously unappreciated challenge posed by asymmetrically distributed pheromone receptors. Cells were able to overcome receptor asymmetry by sensing the ratio, rather than the number, of active pheromone receptors. Second, the polarity cluster proceeded to move erratically around the cortex during an “indecisive phase.” We found evidence that cells switched to a local sensing mechanism during the indecisive phase, wherein cells used the mobile polarity cluster like a nose to search for areas where the local pheromone concentration was high. Third, the polarity cluster stabilized adjacent to a partner cell’s cluster and remained stationary until the partners met in the middle and fused.

β-arrestins (βarrs) interact with G protein-coupled receptors (GPCRs) to desensitize G protein signaling, initiate signaling on their own, and mediate receptor endocytosis.  Using a panel of GPCRs believed to couple differently to βarrs we demonstrate how distinct conformations of GPCR–βarr complexes are specialized to perform different subsets of these cellular functions. Our results thus provide a new signaling paradigm for the understanding of GPCRs, whereby a specific GPCR–βarr conformation mediates receptor desensitization, while another drives internalization and some forms of signaling.

In addition, some GPCRs activate G proteins from within internalized cellular compartments resulting in sustained signaling. We used a variety of biochemical, biophysical, and cell-based methods to demonstrate the existence, functionality, and architecture of internalized receptor “mega-complexes” composed of a single GPCR, βarr, and G protein. EM of purified ‘megaplexes’ reveals that a single receptor binds simultaneously through its core region with G protein and with βarr in the tail conformation. Thus, the two GPCR–βarr conformations carry out distinct cellular functions.

The loss of nigrostriatal dopaminergic neurons is the fundamental hallmark of Parkinson’s disease (PD). In early PD stages, this is ameliorated by dopamine (DA) supplementation; however, as the disease progresses, the complete loss of this key dopaminergic pathway forces the central nervous system to find alternative routes to regain motor control. It has previously been shown that serotonergic routes must take on the role of the failed dopaminergic system throughout the progression of the disease. Previously studied 5-HT1A anxiolytic and anti-depressive therapeutics have yet to be successfully repurposed for Parkinson’s disease patients. Herein is described the current efforts towards the employment non-dopaminergic agonists in the investigation of motor control in Parkinson’s disease. This research outlines the development of non-dopaminergic therapeutics inspired by the core structure of the clinically approved 5-HT1A agonist Befiradol. This motif has been infused with a trans-2-arylcyclopropylamine moiety which has been independently shown to reduce motor symptoms in Parkinson’s disease via a prior collaboration from the McCafferty lab. While it was originally hypothesized that these therapeutics would act as bifunctional agonists at the 5-HT1A and M4 GPCRs, affinity assays reveal dualistic agonism at the 5-HT1A and 1 receptors, offering a new class of potential bifunctional therapeutics.

G protein-coupled receptors (GPCRs) are the largest class of receptors in the human genome and one of the most common drug targets. It is now well-established that GPCRs can signal through multiple transducers, including heterotrimeric G proteins, G protein receptor kinases, and beta-arrestins. Certain ligands can preferentially activate certain signaling cascades while inhibiting others, a phenomenon referred to as biased signaling. While biased signaling is observed in many ex-vivo assays, the physiological relevance of biased signaling is not well established. Using the chemokine receptor CXCR3, a receptor that regulates T cell function, and its endogenous chemokines CXCL9, CXCL10, and CXCL11, I established that endogenous biased signaling exists at CXCR3. After identifying small molecule biased CXCR3 agonists using cell-based assays, I utilized human samples and mouse models of T cell movement and inflammation to determine that differential activation of either the G protein or beta-arrestin signaling pathways downstream of CXCR3 produces distinct functional differences. I identified that beta-arrestin regulated-Akt signaling appears critical for full efficacy chemotaxis. I conclude that biased signaling at CXCR3 produces distinct physiological responses.